Pioglitazone and bladder cancer: FDA's assessment

Pharmacoepidemiol Drug Saf. 2017 Feb;26(2):117-118. doi: 10.1002/pds.4154. Epub 2017 Jan 9.

Authors

Christian Hampp¹, Jennifer Pippins²

Affiliations

¹ Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
² Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

PMID: 28067434
DOI: 10.1002/pds.4154

No abstract available

Publication types

Review

MeSH terms

Humans
Hypoglycemic Agents / adverse effects*
Pioglitazone / adverse effects*
Randomized Controlled Trials as Topic / methods
United States / epidemiology
United States Food and Drug Administration / legislation & jurisprudence*
Urinary Bladder Neoplasms / chemically induced*
Urinary Bladder Neoplasms / diagnosis
Urinary Bladder Neoplasms / epidemiology*

Substances

Hypoglycemic Agents
Pioglitazone